Atenolol versus losartan in children and young adults with Marfan's syndrome
Academic Article
Overview
MeSH Major
Adrenergic beta-Antagonists
Angiotensin II Type 1 Receptor Blockers
Aorta
Aortic Aneurysm
Atenolol
Losartan
Marfan Syndrome
abstract
Among children and young adults with Marfan's syndrome who were randomly assigned to losartan or atenolol, we found no significant difference in the rate of aortic-root dilatation between the two treatment groups over a 3-year period. (Funded by the National Heart, Lung, and Blood Institute and others; ClinicalTrials.gov number, NCT00429364.).